STOCK TITAN

[SCHEDULE 13G/A] Chimerix, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed a Schedule 13G/A reporting that they beneficially own 0.00 shares of Chimerix common stock, representing 0.0% of the class. The cover pages show 0.00 sole and shared voting power and 0.00 sole and shared dispositive power, indicating no reportable economic or voting stake in the issuer as disclosed.

The filing includes a joint filing agreement and an exhibit identifying Goldman Sachs & Co. LLC as a subsidiary of The Goldman Sachs Group, Inc. It also states ownership is five percent or less and that the securities are held in the ordinary course of business and were not acquired to influence control.

The Goldman Sachs Group, Inc. e Goldman Sachs & Co. LLC hanno presentato uno Schedule 13G/A riportando di detenere beneficiariamente 0.00 azioni ordinarie di Chimerix, corrispondenti al 0.0% della classe. Le pagine di copertina indicano 0.00 potere di voto, sia esclusivo che condiviso, e 0.00 potere dispositvo, sia esclusivo che condiviso, segnalando l'assenza di una partecipazione economica o di voto rilevante nell'emittente come dichiarato.

La comunicazione include un accordo di deposito congiunto e un allegato che identifica Goldman Sachs & Co. LLC come società controllata di The Goldman Sachs Group, Inc. Si dichiara inoltre che la partecipazione è pari o inferiore al cinque percento e che i titoli sono detenuti nell'ordinario corso degli affari e non sono stati acquisiti per influenzare il controllo.

The Goldman Sachs Group, Inc. y Goldman Sachs & Co. LLC presentaron un Schedule 13G/A informando que poseen beneficiariamente 0.00 acciones ordinarias de Chimerix, que representan el 0.0% de la clase. Las páginas de portada muestran 0.00 poder de voto, tanto exclusivo como compartido, y 0.00 poder dispositvo, tanto exclusivo como compartido, indicando que no existe una participación económica o de voto reportable en el emisor según lo declarado.

La presentación incluye un acuerdo de presentación conjunta y un anexo que identifica a Goldman Sachs & Co. LLC como subsidiaria de The Goldman Sachs Group, Inc. También señala que la participación es del cinco por ciento o menos y que los valores se mantienen en el curso ordinario del negocio y no fueron adquiridos para influir en el control.

The Goldman Sachs Group, Inc.Goldman Sachs & Co. LLC는 Schedule 13G/A를 제출하여 Chimerix 보통주를 실질적으로 0.00주 보유하고 있으며 이는 해당 클래스의 0.0%에 해당한다고 보고했습니다. 표지에는 단독 및 공동 의결권이 각각 0.00주, 단독 및 공동 처분권이 각각 0.00주로 기재되어 있어 발행회사에 대한 보고 대상의 경제적 또는 의결권 지분이 없음을 나타냅니다.

해당 제출서류에는 공동 제출 계약과 Goldman Sachs & Co. LLC를 The Goldman Sachs Group, Inc.의 자회사로 명시한 첨부 서류가 포함되어 있습니다. 또한 보유 지분이 5% 이하이며, 증권은 통상적인 영업 과정에서 보유되고 통제에 영향을 미치기 위해 취득된 것이 아님을 명시하고 있습니다.

The Goldman Sachs Group, Inc. et Goldman Sachs & Co. LLC ont déposé un Schedule 13G/A déclarant détenir à titre bénéficiaire 0.00 actions ordinaires de Chimerix, représentant 0.0% de la catégorie. Les pages de couverture indiquent 0.00 pouvoirs de vote, tant exclusifs que partagés, et 0.00 pouvoirs de disposition, tant exclusifs que partagés, ce qui signifie qu'il n'existe, selon la déclaration, aucune participation économique ou de vote devant être signalée chez l'émetteur.

Le dépôt comprend un accord de dépôt conjoint et une annexe identifiant Goldman Sachs & Co. LLC comme filiale de The Goldman Sachs Group, Inc. Il précise également que la participation est de cinq pour cent ou moins et que les titres sont détenus dans le cours normal des affaires et n'ont pas été acquis dans le but d'influencer le contrôle.

The Goldman Sachs Group, Inc. und Goldman Sachs & Co. LLC haben eine Schedule 13G/A eingereicht, in der sie angeben, wirtschaftlich begünstigt 0.00 Aktien der Stammaktien von Chimerix zu besitzen, was 0.0% der Klasse entspricht. Die Deckblätter zeigen 0.00 alleinige und gemeinsame Stimmrechte sowie 0.00 alleinige und gemeinsame Verfügungsrechte, was darauf hinweist, dass nach den Angaben keine meldepflichtige wirtschaftliche oder stimmberechtigte Beteiligung am Emittenten besteht.

Die Einreichung enthält eine Vereinbarung über eine gemeinsame Einreichung sowie einen Anhang, der Goldman Sachs & Co. LLC als Tochtergesellschaft von The Goldman Sachs Group, Inc. ausweist. Außerdem wird angegeben, dass die Beteiligung fünf Prozent oder weniger beträgt und dass die Wertpapiere im normalen Geschäftsverlauf gehalten werden und nicht zum Zweck der Einflussnahme auf die Kontrolle erworben wurden.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Report shows no beneficial holdings—no direct market exposure or voting influence from Goldman Sachs entities.

The Schedule 13G/A discloses 0.00 shares and 0.0% ownership, with 0.00 reported voting and dispositive powers. For investors, this filing confirms that these large financial entities do not hold a reportable position in Chimerix and, per the certification, are not acting to influence control. The joint filing and subsidiary identification are administrative disclosures clarifying corporate relationships among the filers.

TL;DR: Disclosure is routine and non-material; it documents corporate relationships and ordinary-course holdings.

The document provides standard compliance information: a joint filing agreement and an exhibit stating the parent-subsidiary relationship. The filers certify the holdings are ordinary-course and not intended to affect corporate control. Because reported holdings are 0.00 shares, there are no governance or control implications arising from this filing itself.

The Goldman Sachs Group, Inc. e Goldman Sachs & Co. LLC hanno presentato uno Schedule 13G/A riportando di detenere beneficiariamente 0.00 azioni ordinarie di Chimerix, corrispondenti al 0.0% della classe. Le pagine di copertina indicano 0.00 potere di voto, sia esclusivo che condiviso, e 0.00 potere dispositvo, sia esclusivo che condiviso, segnalando l'assenza di una partecipazione economica o di voto rilevante nell'emittente come dichiarato.

La comunicazione include un accordo di deposito congiunto e un allegato che identifica Goldman Sachs & Co. LLC come società controllata di The Goldman Sachs Group, Inc. Si dichiara inoltre che la partecipazione è pari o inferiore al cinque percento e che i titoli sono detenuti nell'ordinario corso degli affari e non sono stati acquisiti per influenzare il controllo.

The Goldman Sachs Group, Inc. y Goldman Sachs & Co. LLC presentaron un Schedule 13G/A informando que poseen beneficiariamente 0.00 acciones ordinarias de Chimerix, que representan el 0.0% de la clase. Las páginas de portada muestran 0.00 poder de voto, tanto exclusivo como compartido, y 0.00 poder dispositvo, tanto exclusivo como compartido, indicando que no existe una participación económica o de voto reportable en el emisor según lo declarado.

La presentación incluye un acuerdo de presentación conjunta y un anexo que identifica a Goldman Sachs & Co. LLC como subsidiaria de The Goldman Sachs Group, Inc. También señala que la participación es del cinco por ciento o menos y que los valores se mantienen en el curso ordinario del negocio y no fueron adquiridos para influir en el control.

The Goldman Sachs Group, Inc.Goldman Sachs & Co. LLC는 Schedule 13G/A를 제출하여 Chimerix 보통주를 실질적으로 0.00주 보유하고 있으며 이는 해당 클래스의 0.0%에 해당한다고 보고했습니다. 표지에는 단독 및 공동 의결권이 각각 0.00주, 단독 및 공동 처분권이 각각 0.00주로 기재되어 있어 발행회사에 대한 보고 대상의 경제적 또는 의결권 지분이 없음을 나타냅니다.

해당 제출서류에는 공동 제출 계약과 Goldman Sachs & Co. LLC를 The Goldman Sachs Group, Inc.의 자회사로 명시한 첨부 서류가 포함되어 있습니다. 또한 보유 지분이 5% 이하이며, 증권은 통상적인 영업 과정에서 보유되고 통제에 영향을 미치기 위해 취득된 것이 아님을 명시하고 있습니다.

The Goldman Sachs Group, Inc. et Goldman Sachs & Co. LLC ont déposé un Schedule 13G/A déclarant détenir à titre bénéficiaire 0.00 actions ordinaires de Chimerix, représentant 0.0% de la catégorie. Les pages de couverture indiquent 0.00 pouvoirs de vote, tant exclusifs que partagés, et 0.00 pouvoirs de disposition, tant exclusifs que partagés, ce qui signifie qu'il n'existe, selon la déclaration, aucune participation économique ou de vote devant être signalée chez l'émetteur.

Le dépôt comprend un accord de dépôt conjoint et une annexe identifiant Goldman Sachs & Co. LLC comme filiale de The Goldman Sachs Group, Inc. Il précise également que la participation est de cinq pour cent ou moins et que les titres sont détenus dans le cours normal des affaires et n'ont pas été acquis dans le but d'influencer le contrôle.

The Goldman Sachs Group, Inc. und Goldman Sachs & Co. LLC haben eine Schedule 13G/A eingereicht, in der sie angeben, wirtschaftlich begünstigt 0.00 Aktien der Stammaktien von Chimerix zu besitzen, was 0.0% der Klasse entspricht. Die Deckblätter zeigen 0.00 alleinige und gemeinsame Stimmrechte sowie 0.00 alleinige und gemeinsame Verfügungsrechte, was darauf hinweist, dass nach den Angaben keine meldepflichtige wirtschaftliche oder stimmberechtigte Beteiligung am Emittenten besteht.

Die Einreichung enthält eine Vereinbarung über eine gemeinsame Einreichung sowie einen Anhang, der Goldman Sachs & Co. LLC als Tochtergesellschaft von The Goldman Sachs Group, Inc. ausweist. Außerdem wird angegeben, dass die Beteiligung fünf Prozent oder weniger beträgt und dass die Wertpapiere im normalen Geschäftsverlauf gehalten werden und nicht zum Zweck der Einflussnahme auf die Kontrolle erworben wurden.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



THE GOLDMAN SACHS GROUP, INC.
Signature:Name: Veronica Mupazviriwo
Name/Title:Attorney-in-fact
Date:07/17/2025
GOLDMAN SACHS & CO. LLC
Signature:Name: Veronica Mupazviriwo
Name/Title:Attorney-in-fact
Date:07/17/2025
Exhibit Information

EXHIBIT (99.1) JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, par value $0.001 per share, of CHIMERIX, INC. and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G. Date: 07/17/2025 THE GOLDMAN SACHS GROUP, INC. By:/s/ Veronica Mupazviriwo ---------------------------------------- Name: Veronica Mupazviriwo Title: Attorney-in-fact GOLDMAN SACHS & CO. LLC By:/s/ Veronica Mupazviriwo ---------------------------------------- Name: Veronica Mupazviriwo Title: Attorney-in-fact EXHIBIT (99.2) ITEM 7 INFORMATION The securities being reported on by The Goldman Sachs Group, Inc. ("GS Group"), as a parent holding company, are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC ("Goldman Sachs"), a broker or dealer registered under Section 15 of the Act and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940. Goldman Sachs is a subsidiary of GS Group.

FAQ

What does the Schedule 13G/A say about Goldman Sachs' stake in Chimerix (CMRX)?

The filing reports 0.00 shares, representing 0.0% of Chimerix common stock, indicating no beneficial ownership as disclosed.

Which entities filed the Schedule 13G/A for CMRX?

The filers are The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC.

Do the filers claim any voting or dispositive power over CMRX shares?

No. The cover pages report 0.00 sole and shared voting power and 0.00 sole and shared dispositive power.

Does the filing indicate a significant ownership (over 5%) of CMRX?

No. The filing states ownership is 5 percent or less of the class.

Is there a joint filing or subsidiary disclosure in the filing?

Yes. Exhibit (99.1) is a joint filing agreement and Exhibit (99.2) identifies Goldman Sachs & Co. LLC as a subsidiary of The Goldman Sachs Group, Inc.
Chimerix

NASDAQ:CMRX

CMRX Rankings

CMRX Latest News

CMRX Stock Data

354.50M
91.95M
6.75%
52.9%
5.26%
Biotechnology
Pharmaceutical Preparations
Link
United States
DURHAM